ProcuraAxisBeta
Sign inCreate Free Account
Home / Opportunities / Opportunity
PROCUREMENT OPPORTUNITY

Manufacture and testing of overencapsulated tablets and placebo capsules for research purposes - LAMDARCT clinical trial

Belfast Health & Social Care Trust · Contract details notice on Find a Tender

Tender information last checkedLast checked 5 Oct 2026, 04:53.

Opportunity overview

This procurement is for the manufacture and testing of over encapsulated tablets and placebo capsules for research purposes - LAMDARCT clinical trial

Awarded to

Amounts belong to published awards or contracts. Where several suppliers share one value, it is labelled as shared and is not a supplier-specific allocation.

ALMAC CLINICAL SERVICES LIMITED

Matched by number
Contract value
£494.4k
Awarded
Not supplied
Contract signed
19 Jan 2026
Including VAT
£593.3k
Award ID
1
Status
active
Identifier
GB-COH NI041905
Location
Craigavon, UKN07, BT63 5QD, United Kingdom

Classification

No classification was supplied.

Lots

  • Lot 1Value not stated

Documents and notices

Published notice details

Additional information from the published procurement release. Fields appear only when supplied by the source; check the original notice and tender documents before acting.

Scope, procedure and submissions

Id
DAC20211
Status
complete
Procurement Method
direct
Procurement Method Details
Direct award
Why this procedure was chosen
Schedule 5, (2) The public contract concerns the production of a prototype, or supply of other novel goods or services, for the purpose of (c) other research, experiment, study or development. Age-related macular degeneration (AMD) is a leading cause of visual loss. There are two main forms of AMD: dry and wet. The current wet AMD treatment is intravitreal antiVEGF injections, repeated every 4-12 weeks. Due to the cost of the medication, the route and frequency of administration, this treatment is a significant burden on the NHS budget. An additional treatment option for wet AMD is L-dopa. L-dopa is a widely available drug (used in treatment of Parkinson's), typically in the form of Carbidopa-L-Dopa. It is taken as an oral tablet and is significantly cheaper than the antiVEGF injections. The study will be a placebo-controlled clinical trial. Eligible patients will be randomised to receive either 100mg L-DOPA+25mg carbidopa or placebo twice a day, for 24 months, in addition to the current standard of care to determine if this is a more cost-effective and easier-to-administer treatment regime than the current standard of care. To 'blind' this clinical trial (to reduce bias) requires the development, manufacture and testing of over encapsulated 100mg L-DOPA+25mg carbidopa tablets and development and manufacture of matching placebo capsules. The expertise required to develop and manufacture these capsules in the quantity required for this trial requires outsourcing to a manufacturer licensed by the MHRA possessing the necessary technical expertise.

Legal basis

Id
2023/54
Scheme
UKPGA

Procedure reasons

Entry 1
Id
prototypesDevelopment

Lots and requirements

Entry 1
Id
1
Status
complete

Published documents

Entry 1
Id
conflictOfInterest
Document Type
conflictOfInterest
Description
Not published

Buyer, suppliers and contacts

Organisation 1
Name
Belfast Health & Social Care Trust
Id
GB-PPON-PLQJ-5727-JCLR

Identifier

Scheme
GB-PPON
Id
PLQJ-5727-JCLR

Address

Street Address
Trust Headquarters, 2nd Floor, Non Clinical Support Building, Royal Victoria Hospital
Locality
Belfast
Postal Code
BT12 6BA
Country
GB
Country Name
United Kingdom
Region
UKN06

Contact

Roles

buyer

Details

Classifications

Entry 1
Scheme
UK_CA_TYPE
Id
publicAuthorityCentralGovernment
Description
Public authority - central government
Entry 2
Scheme
UK_CA_DEVOLVED_REGULATIONS
Id
GB-NIR
Description
Northern Irish devolved regulations apply
Organisation 2
Name
ALMAC CLINICAL SERVICES LIMITED
Id
GB-COH-NI041905

Identifier

Scheme
GB-COH
Id
NI041905

Additional Identifiers

Entry 1
Scheme
GB-PPON
Id
PRCD-2287-GMQG

Address

Street Address
Almac House
Locality
Craigavon
Postal Code
BT63 5QD
Country
GB
Country Name
United Kingdom
Region
UKN07

Contact

Roles

supplier

Details

Scale
large
Vcse
No
Public Service Mission Organization
No
Sheltered Workshop
No

Award information

Award 1
Id
1
Status
active
Main Procurement Category
goods

Items

Item 1
Id
1
Related Lot
1

Additional Classifications

Entry 1
Scheme
CPV
Id
33600000
Description
Pharmaceutical products

Delivery locations

Entry 1
Region
UKN
Country
GB
Country Name
United Kingdom

Suppliers

Supplier 1
Id
GB-COH-NI041905
Name
ALMAC CLINICAL SERVICES LIMITED

Related lots

1

Contracts and changes

Entry 1
Id
1
Award ID
1
Title
Manufacture and testing of overencapsulated tablets and placebo capsules for research purposes - LAMDARCT clinical trial
Status
active
Above Threshold
Yes
Date Signed
19 Jan 2026, 00:00
No Agreed Metrics Rationale
The Contract is below the £5M threshold for KPI's

Period

Starts
19 Jan 2026, 00:00
Ends
5 Jan 2030, 23:59

Value

Including VAT
593,337
Amount
494,447.5
Currency
GBP

Documents

Entry 1
Id
005092-2026
Document Type
contractNotice
Notice Type
UK7
Description
Contract details notice on Find a Tender
Published
21 Jan 2026, 09:15
Format
text/html

Recorded locations

  • Buyer location · Belfast · UKN06 · BT12 6BA · United Kingdom

Notice and amendment history

1 published notice version reviewed by ProcuraAxis.

1 VERSION
  1. 005092-2026Contract details notice on Find a Tender ·